The goal of this clinical trial is to evaluate the efficacy of stereotactic radiotherapy in the treatment of brain metastases. The main question it aims to answer is: Did stereotactic radiotherapy improve LC rate in the treatment of brain metastases? Participants will be recorded for local control rates during follow-up.
Age between 18 and 80 years (inclusive), regardless of gender.
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
Diagnosis of brain metastasis confirmed by histopathological examination and/or imaging, and deemed suitable for stereotactic radiotherapy according to the investigator's judgment.
Tumor diameter of brain metastasis ≤ 4 cm, with ≤ 10 metastatic lesions.
Expected survival time < 6 months.
Patients requiring surgical treatment or other local therapies for the target lesions during radiotherapy.
Patients who have received other local treatments (including radiofrequency ablation, cryoablation, particle therapy, etc.) within 30 days prior to screening, or those who have received systemic therapy (chemotherapy, endocrine therapy, immunotherapy) within 14 days or less than five half-lives of a drug prior to screening (whichever is longer).
Patients who have previously received radiotherapy at the same site or for the same lesion.